Skip to main content

We are excited to welcome Engimmune Therapeutics as our newest portfolio company!

Two male scientists loking at samples through microscopes - Renting a lab in Switzerland

Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on T cell receptor (TCR) targeting of solid tumors. By applying functional high-throughput screening coupled with advanced computational methods, Engimmune addresses key efficacy and safety challenges that currently limit the full potential of TCR-T cell and soluble TCR therapeutics.

Share this article

View all news

Sign up to receive our newsletter in your inbox.